Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.
Esophageal Neoplasms|Stomach Neoplasms
DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Epirubicin|DRUG: Oxaliplatin
The proportion of participants alive one year after randomisation, Three and a half years
Time to progression or death due to any cause, Three and a half years|Number of participants with grade 3 and 4 toxicities caused by treatments, Day 1 of every cycle and 30 days after completion of treatment|Time until death due to any cause, Three and a half years|Changes in quality-of-life, Three and a half years|The proportion of participants who have carboplatin, docetaxel and capecitabine re-induced, Five years|Registration of further lines of therapy, Five years
Analysis of cmet by immunohistochemistry, Analysis of archived tumour tissue (primary biopsy, previous surgical resection specimen if available) and metastatic tumour tissue for consenting subjects., Three and a half years
The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.